Business Context and Reporting Period
This Form 6-K filing by Hong Kong Pharma Digital Technology Holdings Limited (the "Company") was submitted on November 24, 2025. The filing serves as a notice regarding the upcoming Annual General Meeting of Shareholders. Note: While the request metadata references "Cellyan Biotechnology Co., Ltd," the filing text explicitly identifies the registrant as Hong Kong Pharma Digital Technology Holdings Limited.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice for a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The document focuses solely on corporate governance procedures.
Guidance, Outlook, and Corporate Actions
The Company announced the following corporate actions and governance updates:
- Annual General Meeting (AGM): Scheduled for December 12, 2025, at 10:00 a.m. Hong Kong Time (9:00 p.m. Eastern Time).
- Location: Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong.
- Key Documents Filed:
- Proxy Statement and Notice of AGM.
- Form of Proxy Card.
- 2025 Equity Incentive Plan.
- Fourth amended and restated memorandum and articles of association.
The filing does not contain specific management commentary on business outlook, risks, or contingencies beyond the standard procedural notices.
Investor Verification Checklist
- Verify the correct registrant name (Hong Kong Pharma Digital Technology Holdings Limited) against the metadata reference (Cellyan Biotechnology Co., Ltd).
- Confirm the date and time of the AGM (December 12, 2025) for voting purposes.
- Review the attached 2025 Equity Incentive Plan for potential dilution impacts.
- Examine the fourth amended and restated memorandum and articles of association for changes to corporate governance or shareholder rights.
- Locate the full Proxy Statement (Exhibit 99.1) for detailed agenda items and director nominations not summarized in this notice.